Murali Doraiswamy, MD brings respected research in Alzheimer’s, brain aging.
CHALFONT, PA – August 20, 2012 – Genomind, a personalized medicine company for neuropsychiatry, today announced the addition of a new member to its leading Scientific Advisory Board.
P. Murali Doraiswamy, MD is a professor in the department of psychiatry at Duke University Medical Center. He is also a professor in medicine at Duke University and a member of the Duke Institute for Brain Sciences.
Dr. Doraiswamy is a respected and globally recognized researcher focusing on intervention and treatment possibilities for Alzheimer’s and other memory disorders. He has served as an advisor to leading government agencies and pharmaceutical companies, and published more than 200 scientific articles. He is the co-author of The Alzheimer’s Action Plan, as well as the e-book Living Well After a Diagnosis of Alzheimer’s. Dr. Doraiswamy also serves as a brain health advisor for Men’s Healthmagazine, and his research has been featured in media outlets worldwide.
“We are thrilled to welcome Dr. Doraiswamy to the Board,” said Genomind’s Co-founder and Chief Scientific Officer Jay Lombard, DO. “Dr. Doraiswamy’s extensive and impressive research on the brain and aging adds an exciting and critical element to our already diverse and accomplished group, and we know his knowledge and insight will be an important asset to Genomind and our future developments.”
“I am happy to join this eminent group of scientists and physicians who already make up the Genomind Scientific Advisory Board,” said Dr. Doraiswamy. “The company’s forward-thinking approach to developing personalized approaches to neuropsychiatric disorders is exciting and I am looking forward to advising the company in its efforts to bring the latest discoveries in diagnostics and treatment to patients.”
Dr. Doraiswamy received his medical degree, a MB,BS from the University of Madras in India and completed postgraduate training in psychiatry at Duke University. He has received many honors for his research including a certificate of special Congressional recognition for medical services to the community.
Dr. Doraiswamy joins a distinguished group of thought leaders on the Genomind Scientific Advisory Board, all known for their work at the forefront of psychiatric and neurologic research and clinical practice. Board members include Scott T. Aaronson, MD; Maurizio Fava, MD; Allan I. Levey, MD; Anil Malhotra, MD; Roy H. Perlis, MD MSc; and Stephen M. Stahl, MD, PhD.
About the Genecept™ Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacology consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/how-it-works/.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
For more information, contact:
Marketing Manager, Genomind